Pharma News

Rheumatoid Arthritis Drug Restores Skin Color in Vitiligo Patient

  • Posted on: 30 June 2015
  • By: Shalini.Sharma

Vitiligo is a common, psychologically devastating condition that causes skin to lose its pigmentation or color. Current treatments, such as steroid creams and light therapy, are not reliably effective in reversing the disease. A new study says, a drug used for treating rheumatoid arthritis has restored skin color in a female patient suffering from vitiligo -- a common, skin condition where portion of skin loses its pigmentation or color. The report was published in JAMA Dermatology.

Jubilant Life Sciences' receives ANDA approval for levofloxacin tablets

Jubilant Life Sciences Ltd, an integrated global pharmaceuticals and life sciences company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for levofloxacin tablets, 250mg and 500mg. It is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.

Gene Reactivation convert Colorectal Cancer Cells into Normal Tissue

  • Posted on: 29 June 2015
  • By: Shalini.Sharma

Nearly 700,000 people around the world die from colorectal cancer each year. Colorectal cancer is the second leading cause of cancer-related death in developed countries.  Anti-cancer therapies generally involve killing off tumor cells. A new study says, now the cancer cells can be turned back into normal tissue simply by reactivating a single gene.  The study is published in the Cell.

Aurobindo Pharma receive US FDA approval for manufacture and market entacapone tablets and azithromycin for injection

  • Posted on: 29 June 2015
  • By: Shalini.Sharma

Aurobindo Pharma got final approvals from the US FDA of azithromycin for injection USP, 500mg /vial and entacapone tablets. Azithromycin for injection USP, 500mg/vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (azithromycin for injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as community-acquired pneumonia and pelvic inflammatory disease.

Breakthrough arthritis treatment developed by Aus researchers

  • Posted on: 29 June 2015
  • By: PharmaTutor News

Australian researchers have developed a breakthrough vaccine-style therapeutic approach to treat rheumatoid arthritis, a debilitating disease affecting over 450,000 people in the country. Lead researcher Ranjeny Thomas from the University of Queensland's Diamantina Institute said results from the phase one clinical trial demonstrate the new treatment is safe and effective in supressing the immune response.

Single shot of Anti-Malaria Drug Immunize Against Malaria

  • Posted on: 27 June 2015
  • By: Shalini.Sharma

The research conducted by Dundee University, Scotland explained that the newly developed drug could work well against parasites resistant to current treatments of the mosquito-borne disease. Researchers  discovered a new compound, DDD107498 to treat malaria in a single dose, protects people from the disease and prevent the transmission of infection. The research is printed  in the journal 'Nature'.

IPC launches android mobile application for ADR reporting

  • Posted on: 27 June 2015
  • By: Shalini.Sharma

Shri B P Sharma, Secretary Health, Ministry of Health & Family Welfare and Chairman, Indian Pharmacopoeia Commission, Government of India launched an Android Mobile Applications for Adverse Drug Reactions (ADRs) reporting facility to the stakeholders of Pharmacovigilance Programme of India (PvPI). The mobile application for ADR reporting was specifically designed to facilitate the needs of the IPC, to ensure hassle free ADR reporting for the stakeholders. The mobile application is expected to provide a platform for the private healthcare professionals to report ADRs to safeguard and enhance public health by ensuring the safety, efficacy and quality of drugs.

Pages